GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » Cyclically Adjusted Revenue per Share

Incyte (FRA:ICY) Cyclically Adjusted Revenue per Share : €9.90 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Incyte Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Incyte's adjusted revenue per share for the three months ended in Dec. 2023 was €4.104. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.90 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Incyte's average Cyclically Adjusted Revenue Growth Rate was 17.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 22.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Incyte was 36.80% per year. The lowest was -26.20% per year. And the median was 22.80% per year.

As of today (2024-04-28), Incyte's current stock price is €47.59. Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €9.90. Incyte's Cyclically Adjusted PS Ratio of today is 4.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 102.35. The lowest was 4.71. And the median was 21.09.


Incyte Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Incyte's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Cyclically Adjusted Revenue per Share Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.33 4.76 6.75 8.64 9.90

Incyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.64 8.79 9.31 10.18 9.90

Competitive Comparison of Incyte's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PS Ratio falls into.



Incyte Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.104/129.4194*129.4194
=4.104

Current CPI (Dec. 2023) = 129.4194.

Incyte Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.393 99.695 0.510
201406 0.436 100.560 0.561
201409 0.813 100.428 1.048
201412 0.592 99.070 0.773
201503 0.855 99.621 1.111
201506 0.779 100.684 1.001
201509 0.922 100.392 1.189
201512 1.031 99.792 1.337
201603 1.228 100.470 1.582
201606 1.136 101.688 1.446
201609 1.236 101.861 1.570
201612 1.585 101.863 2.014
201703 1.839 102.862 2.314
201706 1.416 103.349 1.773
201709 1.506 104.136 1.872
201712 1.778 104.011 2.212
201803 1.465 105.290 1.801
201806 2.075 106.317 2.526
201809 1.784 106.507 2.168
201812 2.150 105.998 2.625
201903 2.030 107.251 2.450
201906 2.156 108.070 2.582
201909 2.300 108.329 2.748
201912 2.387 108.420 2.849
202003 2.374 108.902 2.821
202006 2.772 108.767 3.298
202009 2.408 109.815 2.838
202012 2.960 109.897 3.486
202103 2.289 111.754 2.651
202106 2.635 114.631 2.975
202109 3.109 115.734 3.477
202112 3.440 117.630 3.785
202203 2.986 121.301 3.186
202206 3.855 125.017 3.991
202209 3.709 125.227 3.833
202212 3.889 125.222 4.019
202303 3.348 127.348 3.402
202306 3.905 128.729 3.926
202309 3.807 129.860 3.794
202312 4.104 129.419 4.104

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Incyte  (FRA:ICY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Incyte's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=47.59/9.9
=4.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 102.35. The lowest was 4.71. And the median was 21.09.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Incyte Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Incyte's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (FRA:ICY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (FRA:ICY) Headlines

No Headlines